Work Here?
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Overview
NTx develops lipid nanoparticle (LNP) platforms to deliver nucleic acid therapies, including mRNA, to specific tissues. Its products are scalable, customizable LNP formulations usable across routes of administration, offered through partnerships, licensing, and direct sales to pharma companies and research institutions. The company differentiates itself with a next‑generation LNP platform and a global network of NanoVation GENErators hubs that foster international collaboration and rapid development. Its goal is to improve delivery efficiency, safety, and durability of genetic medicines to make more diseases manageable or curable.
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
Simplify's Take
What believers are saying
- Novo Nordisk partnership worth $600M licenses lcLNP™ for two lead programs.
- Convergent Ventures funding expands board with Absci and Notch executives.
- Life Sciences BC 'Deal of the Year' award validates lcLNP™ potential.
What critics are saying
- Acuitas licenses superior LNPs to Intellia, eroding NanoVation's share.
- Precision NanoSystems sues for IP infringement, freezing operations.
- FDA clinical holds halt extrahepatic programs due to immune activation.
What makes Nanovation Therapeutics unique
- NanoVation's lcLNP™ enables extrahepatic delivery for cardiometabolic diseases.
- Spin-off from NMIN’s NanoCore with Dominik Witzigmann's LNP expertise.
- Global NanoVation GENErators foster international collaboration hubs.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$300k
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Life Insurance
Performance Bonus
Paid Vacation
Paid Sick Leave
Company Stock Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%Biotech is thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards!
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million to develop genetic medicines. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson and David Main, bringing extensive biotech experience.
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson, CFO and CBO of Absci, and David Main, CEO of Notch Therapeutics, bringing expertise in biotech growth and strategic partnerships.
NanoVation Therapeutics announces expansion of Board of Directors and completion of funding round led by Convergent Ventures.
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases.
Nanovation Therapeutics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
Nanovation Therapeutics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today